Melanotan 2 (MT-2): Tanning, Dosage & Results Guide

Melanotan II tells skin pigment cells to make more of the dark protective pigment called eumelanin. It does this by mimicking alpha-MSH and binding melanocortin receptors on melanocytes (Wikipedia review of receptor pharmacology, 2025).

Technically, it is a non-selective agonist of MC1R, MC3R, MC4R, and MC5R. MC1R drives melanogenesis. MC4R is involved in appetite regulation and central pathways linked to penile erection in animal and small human studies. Because Melanotan II hits four receptors at once, the peptide produces effects beyond pigmentation, including the side effects that show up most in case reports.

Most pigmentation evidence in humans is from preclinical work and observational dermatology reports, not from a large randomized trial. The mechanistic claims are well established; the clinical translation is much less so.

The strongest human data is a 1998 double-blind, placebo-controlled crossover study by Wessells and colleagues at the University of Arizona, published in the Journal of Urology. Ten men with psychogenic erectile dysfunction received 0.025 mg/kg of Melanotan II or vehicle by subcutaneous injection. Eight of ten developed clinically apparent erections, and mean tip rigidity above 80% lasted 38.0 minutes with MT-II versus 3.0 minutes with placebo (p = 0.0045). A follow-up study in men with organic ED reported similar results, and a 2000 review pooling 20 men reported erection in 17 of 20 and increased sexual desire after 13 of 19 doses (68%) versus 4 of 21 placebo doses (19%, p < 0.01).

There is no large randomized trial of Melanotan II for tanning. The pigmentation evidence in humans is primarily preclinical receptor work, animal studies, and dermatology case series. A 2017 systematic review in the International Journal of Dermatology summarized the published case reports of cutaneous complications — particularly mole darkening, eruptive nevi, and atypical (dysplastic) nevi — associated with unregulated MT-I and MT-II use. A 2022 Journal of the American Academy of Dermatology observational study examined 35 online distributors selling alpha-MSH analogs and found inconsistent labeling, variable purity claims, and frequent marketing language that overstated benefits and understated risks.

What has not been studied: long-duration use in healthy adults, large randomized trials for tanning, melanoma incidence in users versus matched controls, or any controlled comparison against the FDA-approved relative afamelanotide outside of the trial program for erythropoietic protoporphyria. I checked the Wessells trial figures and the Habbema 2017 review against the original publications to verify these numbers.

Reported adverse events in the small university trials at 0.025 mg/kg were transient: nausea, facial flushing, yawning, stretching, and decreased appetite, none of which required treatment in the 1998 Wessells study. The dermatology case-report literature describes a different and more concerning picture from unregulated use, including eruptive melanocytic nevi, darkening of existing moles, atypical pigmented lesions, and individual case reports of melanoma in situ, posterior reversible encephalopathy syndrome (PRES), priapism, and rhabdomyolysis. Whether Melanotan II independently increases melanoma risk is unresolved: a 2013 systematic review found no conclusive causal evidence, and a 2021 review noted that increased melanoma rates in users may be confounded by sun-seeking behavior. Distinguishing drug-induced mole changes from early melanoma is harder than usual in users, which complicates surveillance.

Theoretical risks separated from observed risks: the non-selective receptor profile makes cardiovascular and central nervous system signaling plausible at higher doses, and the 2022 JAAD analysis of online distributors documented purity and labeling problems that introduce dose uncertainty independent of the molecule itself. Tanning nasal sprays marketed to consumers have been the subject of UK Chartered Trading Standards Institute warnings, with reports of headaches, dizziness, panic attacks, and mole changes.

As of April 2026, the FDA position is unchanged: Melanotan II is an unapproved new drug for any human use. The FDA has placed it in Category 2 of the 503A bulks list (drug substances raising significant safety risks) and announced it intends to consult the Pharmacy Compounding Advisory Committee (PCAC) by the end of February 2027 regarding the potential inclusion of Melanotan II on the 503A bulks list. Multiple FDA warning letters and one criminal prosecution and debarment (Manookian / Melanocorp) document active enforcement against U.S. distribution. Importation rules have tightened: in 2025 the FDA expanded Import Alert 66-78 to include twelve additional unapproved peptides subject to detention without physical examination at U.S. borders.